Skip to main content
Premium Trial:

Request an Annual Quote

Progenetics to Distribute Biocept's Liquid Biopsy Assays in Israel

NEW YORK (GenomeWeb) – Biocept announced today that cancer genomics firm Progenetics will market and distribute its complete portfolio of Target Selector liquid biopsy assays in Israel. Other terms of the agreement were not disclosed.

Progenetics, founded in 2014 and based in Tel Aviv, Israel, provides advanced tumor profiling services. Last July, it signed an agreement with OncoDNA to provide Israeli physicians with a variety of other cancer tests.

According to its website, Progenetics also has testing collaborations with the Mayo Clinic, Quest Diagnostics, Response Genetics, BioReference Laboratories, NeoGenomics Laboratories, Adaptive Biotechnologies, and Otogenetics.

Raaj Trivedi, Biocept's vice president of commercial operations, said in a statement that the company sees its new agreement with Progenetics as a "model for additional agreements with distributors in select global markets."

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.